Hydrogen Therapy Helps Clear Lupus Skin Rash in Young Woman
- Authors
- Nai-Sung Hsu, Jeng-Wei Lu, Hsiao-Chen Liu, Yi-Jung Ho, Kuang-Yih Wang, Feng-Cheng Liu
- Journal
- SAGE Open Medical Case Reports
- Year
- 2025
- DOI
- 10.1177/2050313X251372755
- Study Type
- Human
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Taiwan
- Health Condition
- Systemic Lupus Erythematosus
- Body System
- Immune System
TL;DR
Adding molecular hydrogen therapy helped clear a persistent lupus rash and improved immune balance in a patient unresponsive to standard treatment.
Key Finding
A single patient with treatment-resistant lupus rash showed clinical improvement and favorable changes in immune markers after adding molecular hydrogen therapy to her standard treatment.
Summary
This case report describes one 27-year-old woman with systemic lupus erythematosus (an autoimmune disease where the body attacks its own tissues) who had a persistent facial rash that didn't improve with standard medication. When she started drinking hydrogen-enriched water as an additional treatment, her rash improved, her fatigue decreased, and blood tests showed changes in immune markers associated with the disease. However, this is a single patient's experience, not a controlled study.
Practical Takeaway
While this case suggests hydrogen water may have potential as an add-on therapy for lupus symptoms, it represents only one person's experience without a comparison group. Much larger, controlled studies are needed before any conclusions can be drawn about whether hydrogen water would help others with lupus. Anyone with lupus should discuss any new treatments with their doctor before trying them.
Abstract
Systemic lupus erythematosus is a chronic autoimmune disease often presenting with cutaneous symptoms such as malar rash. While hydroxychloroquine is standard therapy, some cases remain treatment-resistant. Molecular hydrogen possesses anti-inflammatory and immunomodulatory effects in autoimmune disorders. This case report examines the use of molecular hydrogen as adjunctive therapy in a 27-year-old woman with systemic lupus erythematosus and refractory malar rash. Despite hydroxychloroquine treatment, her rash persisted and significantly impacted the quality of life. After initiating oral molecular hydrogen therapy, the patient showed sustained clinical improvement, including reduced malar rash, decreased fatigue, and enhanced well-being over several months. These outcomes were accompanied by notable immunological changes: increased killer cell lectin-like receptor G1 positive effector T cells, decreased plasmablast activity, stabilization of B cell exhaustion markers, and reductions in and a decline in antinuclear antibody and anti-double-stranded DNA antibody levels. This case suggests that molecular hydrogen may be a safe and promising adjunctive treatment for cutaneous manifestations and systemic immune modulation in systemic lupus erythematosus.